£7.05m total gross proceeds from Fundraise

LONDON and NEW YORK, 26 September 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, confirms, further to the announcements made on 22 September, the result of its Fundraise at the Issue Price of 9.5 pence per share. The Company announces that it has raised aggregate gross proceeds of approximately £0.8 million pursuant to a significantly oversubscribed WRAP Retail Offer, alongside the previously announced oversubscribed Placing, Subscription and Additional Subscription. Accordingly, the Company will issue a total of 8,421,052 new Ordinary Shares at the Issue Price pursuant to the WRAP Retail Offer (the "Retail Offer Shares").

In total, the Placing and Subscription, the Additional Subscription and the WRAP Retail Offer have raised gross proceeds of approximately £7.05 million ($9.5 million) for the Company, via the Placing and Subscription of 54,741,582 Placing and Subscription Shares, 11,000,000 Additional Subscription Shares and the 8,421,052 WRAP Retail Offer Shares.

James McCullough, CEO of Renalytix, commented: "I would like to thank our investors for a significantly oversubscribed fundraise at both the institutional and retail investor level, at a key moment in our commercial growth. We all have a real opportunity to change the course of diabetic kidney disease that causes untold suffering in millions of people and an unsustainable social cost burden. Over the course of coming months we will be working closely with Tempus AI to expand access to kidneyintelX.dkd advanced prognostic blood testing in the US market, along with other developing market opportunities."

Admission

Applications have been made for the First Tranche Placing Shares, the Second Tranche Placing Shares, the Additional Subscription Shares and the Retail Offer Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). Admission of the 9,253,679 First Tranche Placing Shares will become effective at 8.00 a.m. on 26 September 2025. Admission of the 45,487,903 Second Tranche Placing Shares, the 11,000,000 Additional Subscription Shares and the 8,421,052 Retail Offer Shares will become effective at 8.00 a.m. on 29 September 2025.

The Retail Offer Shares will be issued free of all liens, charges and encumbrances and will, on Admission, rank pari passu in all respects with the new Ordinary Shares to be issued pursuant to the Placing, the Subscription, the Additional Subscription and the Company's existing Ordinary Shares.

Director Shareholdings

Following Admission, the percentage holdings of the Directors who participated in the Fundraise are set out in the table below:

*Christopher Mills' shareholding includes shares held through North Atlantic Smaller Companies Investment Trust plc and Oryx International Growth Fund Limited. Christopher Mills is a partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is investment manager to North Atlantic Smaller Companies Investment Trust plc and investment adviser to Oryx International Growth Fund Limited.

Total Voting Rights

Upon Admission, the Company's issued ordinary share capital will consist of 405,368,646 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission the total number of Ordinary Shares and voting rights in the Company will be 405,368,646 . With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms used in this announcement have the meanings given to them in the Company's 'Proposed Fundraise', 'WRAP Retail Offer for up to £500,000' and 'Result of Fundraise' announcements dated 22 September 2025 and the Company's 'Additional Institutional Subscription for 11 million Shares' announcement dated 24 September 2025, unless the context provides otherwise.